Astute Medical, which identifies and validates biomarkers that serve as the basis for diagnostic tests, has raised $500,000 through an offering of rights and securities.
The company raised $40.4m in its series C round in June from venture capital firms Delphi Ventures , De Novo Ventures, Domain Associates, MPM Capital and corporate venturing units Johnson & Johnson Development and Kaiser Permanente Ventures.
Last year, Astute Medical, a US-based provider of laboratory tests, extended its B round by $13m to its existing investment consortium that included Johnson & Jonson’s corporate venturing unit.
Alongside Johnson & Johnson Development Corporation in the B extension are venture capital firms Domain Associates, Delphi Ventures and De Novo Ventures. Astute had initially raised $26.5m in its B round in May.
Founded in 2007 by Christopher Hibberd and Paul McPherson, former managers at diagnostics company Biosite before its acquisition by Inverness Medical Innovations for $1.7bn earlier that year, Astutue had raised $6.2m in it’s A round in May 2008.